Indications and Limitations of Use: ADYNOVATE® [Antihemophilic factor (Recombinant), PEGylated] is a human antihemophilic factor indicated for use in children and adults with hemophilia A for the control and prevention of bleeding episodes. ADYNOVATE is not indicated for the treatment of von Willebrand disease.1
*In clinical trials, ADYNOVATE demonstrated the ability to help prevent bleeding episodes using a prophylaxis regimen.
ADYNOVATE has a simple, twice-weekly dosing schedule on the same 2 days each week, which can help personalize treatment so that your patients have more time to spend doing the other things that make them who they are.1
Designed to Extend FVIII Circulation Time
ADYNOVATE is built on the ADVATE® [Antihemophilic Factor (Recombinant)] molecule, a proven treatment in hemophilia A patients. Created with PEGylation technology, ADYNOVATE was designed to stay in circulation longer than ADVATE, to provide factor coverage.†1-3
†Proprietary PEGylation Technology exclusively licensed from Nektar Therapeutics.
CONTRAINDICATIONS: Prior anaphylactic reaction to ADYNOVATE, to the parent molecule (ADVATE® [Antihemophilic Factor (Recombinant)]), mouse or hamster protein, or excipients of ADYNOVATE (e.g. Tris, mannitol, trehalose, glutathione, and/or polysorbate 80).